findmyKOL
Clinical trialNCT01622348CompletedPhase 2Interventional

Trial of IMO-3100 in Patients With Moderate to Severe Plaque Psoriasis

SponsorIdera Pharmaceuticals, Inc.Enrollment44Actively Extending Plaque PsoriasisModerate to Severe Plaque Psoriasis
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The purpose of this study is to evaluate different dose levels of IMO-3100 compared to placebo administered for 4 weeks to patients with moderate to severe plaque psoriasis.
clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

13 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • Florida Center for Dermatology, P.A

    Jacksonville, Florida, United States

  • Atlanta Dermatology, Vein & Research Center, Pc

    Alpharetta, Georgia, United States

  • Dermatologic Surgery Specialists, Inc.

    Macon, Georgia, United States

  • Indiana Clinical Trials Center, Pc

    Plainfield, Indiana, United States

  • Dermresearch Pllc

    Louisville, Kentucky, United States

  • Mass General Hospital Clinical Unit for Research Trials in Skin

    Boston, Massachusetts, United States

  • Tufts Medical Center

    Boston, Massachusetts, United States

  • Derm Research Center of New York

    Stony Brook, New York, United States

  • Oregon Dermatology and Research Center

    Portland, Oregon, United States

  • Clinical Partners, Inc

    Johnston, Rhode Island, United States

  • J & S Studies

    College Station, Texas, United States

  • Center for Clinical Studies

    Webster, Texas, United States

  • University of Utah, Dermatology

    Salt Lake City, Utah, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

IMO-3100 at 0.16 mg/kgIMO-3100 at 0.32 mg/kgSaline for Injection
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
31 May 2012
Primary completion
30 Nov 2012
Completion
31 Dec 2012
Last update posted
9 Jan 2018
Registered enrollment
44
Registry id
NCT01622348
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.